Last update 11 Dec 2025

Jinlida granules

Overview

Basic Info

Drug Type
Herbal medicine
Synonyms-
Target-
Action-
Mechanism-
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
Diabetes Mellitus
Inactive Indication-
Originator Organization
Shijiazhuang Yiling Pharmaceutical Co., Ltd.Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Active Organization
Shijiazhuang Yiling Pharmaceutical Co., Ltd.Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (18 Mar 2020),
Diabetes Mellitus
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with Jinlida granules
NCT06495814
/ Not yet recruitingPhase 2IIT
Characterization and Mechanism Research of the Pre-disease State of Obese Type 2 Diabetes Mellitus
ChiCTR2500096120
/ Not yet recruitingNot ApplicableIIT
Study on the mechanism of action of Jinlida granules in improving gastrointestinal neuropathy in type 2 diabetes mellitus
ChiCTR2400079843
/ Not yet recruitingNot ApplicableIIT
Effect of Jinlida Granule on Gastrointestinal Autonomic Neuropathy in diabetes
100 Clinical Results associated with Jinlida granules
Login to view more data
100 Translational Medicine associated with Jinlida granules
Login to view more data
100 Patents (Medical) associated with Jinlida granules
Login to view more data
25
Literatures (Medical) associated with Jinlida granules
01 Nov 2024JAMA Internal Medicine
Insights for Using Jinlida in Diabetes Prevention
01 Nov 2024JAMA Internal Medicine
Insights for Using Jinlida in Diabetes Prevention—Reply
01 Nov 2024JAMA Internal Medicine
Insights for Using Jinlida in Diabetes Prevention
100 Deals associated with Jinlida granules
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus
China
Shijiazhuang Yiling Pharmaceutical Co., Ltd.Shijiazhuang Yiling Pharmaceutical Co., Ltd.
18 Mar 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
ChiCTR1900023241 (FOCUS, Pubmed)
ManualManual
Phase 4
Glucose Intolerance | Metabolic Diseases
885
widwsopkct(rzwgmqjmtv): HR = 0.59 (95% CI, 0.46 - 0.74), P-Value = < 0.001
View more
Positive
01 Jul 2024
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free